会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明申请
    • BUTYRYL-TYROSINYL SPERMINE, ANALOGS THEREOF AND METHODS OF PREPARING AND USING SAME
    • 丁基吡咯烷酮,其类似物及其制备和使用方法
    • WO1996022962A1
    • 1996-08-01
    • PCT/US1996001128
    • 1996-01-23
    • THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKNAKANISHI, KojiHUANG, DanwenCHOI, Seok-KiKALIVRETENOS, AristotleGOODNOW, Robert
    • THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    • C07C211/00
    • C07C237/22C07C245/18C07C247/16C07C247/18C07C279/14C07D209/20
    • The present invention provides a compound having structure (I) wherein R1 is a saturated or unsaturated linear or branched chain alkyl group, or a cholestanyl group; wherein R2 ia s 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 4-hydroxyphenyl, 4-(arylalkyloxy)phenyl, 3,4-dihalophenyl, 4-hydroxy-3,5-dihalophenyl, 4-azidophenyl or 4-halophenyl group; wherein R3 is H, a linear or branched chain alkyl or alkenyl group, or a phenyl, 2-azidophenyl, 3-azidophenyl, 4-azidophenyl group, or an alkenylacyl, 3-amino-3-butylpropyl, N-[N-(N-{4-azidobenzoyl}aminopropyl)aminopropyl], cis- or trans-cinnamyl, 2-amino-2-[(4'-azidophenyl)acetyl], (trifluoromethyl)-aminoacetyl or D- or L-arginyl group bonded through the alpha -carbonyl moiety thereof; R4 is H, or a linear or branched chain alkyl group; wherein R5, R6 and R7 are independently the same or different and are H, a linear or branched chain alkyl group, an aryl group or an arylalkyl group; wherein n, j and t are each 0 or 1; wherein m, o, p, q, r and s are independently the same or different and are 0, 1 or 2; wherein r+s and m+o are each equal to 2; wherein, j is 0, p+q is 2; wherein, if j is 1, then p is 1, q is 0 and R6 is H; and wherein * denotes a D or L configuration. The invention also provides a method of synthesizing the compound. Another aspect of the invention concerns a method of treating a subject afflicted by a disorder associated with binding of an etiological agent to a glutamate receptor.
    • 本发明提供具有结构(I)的化合物,其中R1是饱和或不饱和的直链或支链烷基或胆甾烷基; 其中R2是2-吲哚基,3-吲哚基,4-吲哚基,5-吲哚基,4-羟基苯基,4-(芳基烷氧基)苯基,3,4-二卤代苯基,4-羟基-3,5-二卤苯基,4-叠氮基苯基 或4-卤代苯基; 其中R 3为H,直链或支链烷基或烯基,或苯基,2-叠氮基苯基,3-叠氮基苯基,4-叠氮基苯基或链烯基酰基,3-氨基-3-丁基丙基,N- [N-( N-(4-叠氮基苯甲酰基)氨基丙基)氨丙基],顺式或反式肉桂基,2-氨基-2 - [(4'-叠氮基苯基)乙酰基],(三氟甲基) - 氨基乙酰基或D-或L-精氨酰基 其α-羰基部分; R4是H或直链或支链烷基; 其中R5,R6和R7独立地相同或不同,为H,直链或支链烷基,芳基或芳基烷基; 其中n,j和t各自为0或1; 其中m,o,p,q,r和s独立地相同或不同,为0,1或2; 其中r + s和m + o各自等于2; 其中,j为0,p + q为2; 其中,如果j为1,则p为1,q为0且R6为H; 并且其中*表示D或L构型。 本发明还提供了一种合成化合物的方法。 本发明的另一方面涉及一种治疗受病原体与谷氨酸受体的结合相关疾病的受试者的治疗方法。